Literature DB >> 19230534

Allograft reconstruction in malignant bone tumors: indications and limits.

Kevin A Raskin1, Francis Hornicek.   

Abstract

Advances in imaging studies and the growing effectiveness of chemotherapy have enabled musculoskeletal tumor surgeons to narrow their margins and employ limb-salvage surgery as the preferred method for managing bone sarcoma. The reconstructive options available to orthopedic oncologists range from allograft transplantation to endoprosthetic reconstruction to a combination of both. Bone allograft transplantation offers a biologic reconstruction that can restore bone stock and joint kinematics, while sparing the opposing articular surface. This chapter will discuss the limitations, complications, survival rates, and indications for using bone allografts.

Entities:  

Mesh:

Year:  2009        PMID: 19230534     DOI: 10.1007/978-3-540-77960-5_5

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


  4 in total

1.  Intravenous administration of multipotent stromal cells and bone allograft modification to enhance allograft healing.

Authors:  Sharada Paudel; Wen-Han Lee; Moses Lee; Talal Zahoor; Reed Mitchell; Shang-You Yang; Haiqing Zhao; Lew Schon; Zijun Zhang
Journal:  Regen Med       Date:  2019-02-14       Impact factor: 3.806

Review 2.  [Specific intraoperative and secondary complications of biological reconstructions following extralesional tumour resections of malignant bone tumours].

Authors:  B Lehner; G W Omlor; A Geisbüsch; J Bollmann
Journal:  Orthopade       Date:  2020-02       Impact factor: 1.087

3.  Successful treatment of a dedifferentiated chondrosarcoma of the proximal humerus with a hemicortical articular surface sparing allograft: A case report.

Authors:  Charles D Gomez; Mark S Anderson; Scott C Epperly; Lee M Zuckerman
Journal:  Int J Surg Case Rep       Date:  2020-06-25

Review 4.  Strategies for large bone defect reconstruction after trauma, infections or tumour excision: a comprehensive review of the literature.

Authors:  Filippo Migliorini; Gerardo La Padula; Ernesto Torsiello; Filippo Spiezia; Francesco Oliva; Nicola Maffulli
Journal:  Eur J Med Res       Date:  2021-10-02       Impact factor: 2.175

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.